Impact of Atogepant on Functional Outcomes in Trial Completers for the Preventive Treatment of Episodic Migraine: A Post-Hoc Analysis of the ADVANCE Trial (S35.003)
Evaluate the impact of atogepant 60 mg once daily (QD) on functional outcomes in ADVANCE trial completers.
Authors
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Belinda Savage‐Edwards
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Andrew Blumenfeld (ORCID: https://orcid.org/0000-0003-0851-4914)
- Dagny Holle (ORCID: https://orcid.org/0000-0003-4872-0384)
- Umer Najib (ORCID: https://orcid.org/0000-0002-1116-9229)
- Natty Chalermpalanupap
- Yingyi Liu (ORCID: https://orcid.org/0000-0003-2394-5106)
- Jonathan Stokes
Institutions
- West Virginia University (US)
- AbbVie (United States) (US)
- Blanchette Rockefeller Neurosciences Institute (US)
- Pain and Headache Center (US)
- West German Heart and Vascular Center Essen (DE)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208764
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00